BioAlliance Acquired European Rights For Ondansetron Oral Spray To Complement Its Franchise In Cancer Supportive Care From NovaDel Pharma Inc.
BioAlliance Pharma SA (Paris:BIO) a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announced that it has acquired the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD). Ondansetron is the leading 5-HT3 antagonist largely used to prevent nausea and vomiting after chemotherapy, radiation, and surgery (tablets or intravenous forms).
More: continued here
Filed under: Pharma Industry on May 22nd, 2008